Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
about
Abiraterone in prostate cancer: a new angle to an old problemSteroidogenesis in the skin: implications for local immune functionsA comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancerInterplay between genomic alterations and androgen receptor signaling during prostate cancer development and progressionStilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cellsAndrogen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Shared common variants in prostate cancer and blood lipids.Key role of CRF in the skin stress response system.The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.Hormones and prostate carcinogenesis: Androgens and estrogens.Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells.Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.Androgen-Sensitized Apoptosis of HPr-1AR Human Prostate Epithelial Cells.Expression of androgen receptor splice variants in clinical breast cancers.Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironmentAndrogen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axisConstitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines.Prolonged androgen deprivation leads to overexpression of calpain 2: implications for prostate cancer progression.Selective androgen receptor modulators for the treatment of late onset male hypogonadism.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Lipids and prostate cancer.Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.Decoding the androgen receptor splice variants.Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin.Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.Global analysis of transcription in castration-resistant prostate cancer cells uncovers active enhancers and direct androgen receptor targets.Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells.
P2860
Q26828810-21DE4B5D-BE00-41AC-9E7C-2CD8BBD4BCC8Q26830355-65ABCCFE-5A5E-4721-BA5C-004A081F4A40Q27000180-0C6149A7-60E2-40AA-B0B6-C3D50B9C0884Q27022288-2C457230-CB6F-4400-AC2D-8E4F11795FF1Q28539233-12BCDDCB-E123-4272-A76E-57F05408E370Q33621403-4F265810-DE4B-475F-BCA2-F0318FD4243EQ33775717-F2130EA1-5344-4BA6-89EE-3A7E730FD782Q34001263-5F36B89D-B600-443E-A151-1927E43A4831Q34363640-9996AD21-3EE8-4D59-B6CA-94B222A02041Q34522279-1EA6C743-32BD-403D-80C9-254DD5C49A26Q34586300-85A88470-1162-4F7D-98AF-C00A4ECBCDFDQ35009235-3494D692-92F3-43A9-B216-2AB5D11DC32FQ35328550-499ABBDB-5657-4B49-8E15-37B33DB511CEQ35687198-51B44FEF-283A-4BDE-8146-CA29FCEAF79CQ35762232-C7F1AED7-7880-4DF0-A40F-F502F1236B93Q35776234-8E72F85A-4B3B-429A-A917-01510EFA225BQ35868187-921A29DC-909B-4D6C-8B81-98022A71DB7BQ36024044-3B60618E-D7D2-466D-A215-E2E23238277AQ36689084-BEA94AE9-A40D-48B4-AC0A-F2DB85AB7CE0Q36817810-FE467AEA-FFE8-4382-9B28-D29E00170647Q36961208-298D1141-903D-4F11-8C40-31C76D047768Q37093536-64EB8D33-795F-46BB-961A-8EFB8EB38208Q37254115-51D74D2A-0E09-4AFB-81D5-CD30A46B863FQ37504520-30DD1DCA-C692-4173-B9D4-6F98C77287A4Q37639204-9CCF21E6-6B7C-466E-94E9-1F678F6C587BQ37709535-8A3C87AD-2DC3-487C-ACB6-AB638049555AQ38002682-1E900DA2-94F8-4212-A4ED-322F35C8F844Q38165773-10F2149F-7931-40A3-B3E8-E3E2501EF405Q38172209-AB2FA4D6-6BEC-49BC-9337-5FBD5A159536Q38263870-0F7E32ED-DE97-4271-A9BF-66F5F20C411EQ38766081-02F1CC9D-D05E-4F09-9240-9F6557AE1D67Q38924091-8C3C5E66-FBE2-41CB-B8AC-642780891F10Q38973231-ADFCF32A-1DB8-452E-953B-A668B0070364Q39003326-BAB58125-0CBC-4172-890E-E51E3E482CE0Q39085996-C47CDF08-2BFE-480E-BE24-92644727E6F9Q39270073-6834563D-ED0B-49FA-989D-6867BD852503Q39376859-D7471DB7-3301-4527-AAD2-FFD51AF6091AQ39647282-0C7FFADB-0028-4D8A-8F42-AD27414AF22CQ41812923-60EAC290-33DF-4449-AB51-036638A81E08Q42288618-29B4A63C-510E-4E28-A508-02AC4CE9B402
P2860
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intratumoral androgen biosynth ...... nesis and response to therapy.
@en
Intratumoral androgen biosynth ...... nesis and response to therapy.
@nl
type
label
Intratumoral androgen biosynth ...... nesis and response to therapy.
@en
Intratumoral androgen biosynth ...... nesis and response to therapy.
@nl
prefLabel
Intratumoral androgen biosynth ...... nesis and response to therapy.
@en
Intratumoral androgen biosynth ...... nesis and response to therapy.
@nl
P2860
P356
P1476
Intratumoral androgen biosynth ...... nesis and response to therapy.
@en
P2093
Changmeng Cai
Steven P Balk
P2860
P304
P356
10.1530/ERC-10-0339
P577
2011-08-30T00:00:00Z